Etentamig

Product Description: Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]D'Souza A, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 Nov 1;40(31):3576-3586.

Molecular Weight: N/A

Compound Purity: 99

Research Area: Cancer; Inflammation/Immunology; Cardiovascular Disease

Target: CD3

• Artikelnummer: MEXHY-P990785-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P990785-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated